Evidence map›Paper›PMID 35028629›Full record

ArticleThe Lancet regional health. Western Pacific2022

The impact of 10-valent pneumococcal vaccine introduction on invasive disease in Fiji.

R Reyburn, E J Tuivaga, F T Ratu, E M Dunne, D Nand, J Kado, K Jenkins, L Tikoduadua, A Jenney, B P Howden and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Lancet regional health. Western Pacific, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 5 countries.

R ReyburnMurdoch Children's Research Institute, Melbourne, Victoria, Australia.
E J TuivagaThe Ministry of Health and Medical Services, Suva, Fiji.
F T RatuThe Ministry of Health and Medical Services, Suva, Fiji.
E M DunneMurdoch Children's Research Institute, Melbourne, Victoria, Australia.
D NandThe Ministry of Health and Medical Services, Suva, Fiji.
J KadoFiji National University, Suva, Fiji.
K JenkinsAustralia's support to the Fiji health sector, Suva, Fiji.
L TikoduaduaThe Ministry of Health and Medical Services, Suva, Fiji.
A JenneyMurdoch Children's Research Institute, Melbourne, Victoria, Australia.
B P HowdenMicrobiological Diagnostic Unit Public Health Laboratory, The University of Melbourne at the Peter Doherty Institute of Infection and Immunity, Melbourne, Australia.
S A BallardMicrobiological Diagnostic Unit Public Health Laboratory, The University of Melbourne at the Peter Doherty Institute of Infection and Immunity, Melbourne, Australia.
K FoxRegional Office for the Western Pacific, World Health Organization, Manila, Philippines.
R DeviThe Ministry of Health and Medical Services, Suva, Fiji.
C SatzkeMurdoch Children's Research Institute, Melbourne, Victoria, Australia.
E RafaiThe Ministry of Health and Medical Services, Suva, Fiji.
M KamaThe Ministry of Health and Medical Services, Suva, Fiji.
S FlascheCentre for Mathematical Modelling for Infectious diseases, London School of Hygiene and Tropical Medicine, London, UK.
E K MulhollandMurdoch Children's Research Institute, Melbourne, Victoria, Australia.
F M RussellMurdoch Children's Research Institute, Melbourne, Victoria, Australia.
Ministry Of Health · FJThe University of Melbourne · AUFiji National University · FJLondon School of Hygiene & Tropical Medicine · GBMurdoch Children's Research Institute · AUCenters for Disease Control and Prevention · US

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundIn 2012, Fiji introduced the 10-valent pneumococcal conjugate vaccine (PCV10). We assessed the impact of PCV10 on invasive pneumococcal disease (IPD), probable bacterial or pneumococcal meningitis (PBPM), meningitis and sepsis 3-5 years post-introduction.

methodsLaboratory-confirmed IPD and PBPM cases were extracted from national laboratory records. ICD-10-AM coded all-cause meningitis and sepsis cases were extracted from national hospitalisation records. Incidence rate ratios were used to compare outcomes pre/post-PCV10, stratified by age groups: 1-23m, 2-4y, 5-9y, 10-19y, 20-54y, ≥55y. To account for different detection and serotyping methods in the pre-and post-PCV10 period, a Bayesian inference model estimated serotype-specific changes in IPD, using pneumococcal carriage and surveillance data.

findingsThere were 423 IPD, 1,029 PBPM, 1,391 all-cause meningitis and 7,611 all-cause sepsis cases. Five years post-PCV10 introduction, IPD declined by 60% (95%CI: 37%, 76%) in children 1-23m months old, and in age groups 2-4y, 5-9y, 10-19y although confidence intervals spanned zero. PBPM declined by 36% (95%CI: 21%, 48%) among children 1-23 months old, and in all other age groups, although some confidence intervals spanned zero. Among children <5y of age, PCV10-type IPD declined by 83% (95%CI; 70%, 90%) and with no evidence of change in non-PCV10-type IPD (9%, 95%CI; -69, 43%). There was no change in all-cause meningitis or sepsis. Post-PCV10, the most common serotypes in vaccine age-eligible and non-age eligible people were serotypes 8 and 23B, and 3 and 7F, respectively. INTERPRETATIONS: Our study demonstrates the effectiveness of PCV10 against IPD in a country in the Asia-Pacific of which there is a paucity of data.

fundingThis study was support by the Department of Foreign Affairs and Trade of the Australian Government and Fiji Health Sector Support Program (FHSSP). FHSSP is implemented by Abt JTA on behalf of the Australian Government.

Identifiers

PMID35028629
PMCPMC8741523
OpenAlexW4206532717

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.